Pharmaceuticals
Company Overview of Xellia Pharmaceuticals AS
Company Overview
Harbitzalléen 3
P.O.Box 158
Skøyen
Oslo, 0212
Norway
Founded in 1994
Key Executives for Xellia Pharmaceuticals AS
Xellia Pharmaceuticals AS Key Developments
3i Group plc (LSE:III) is in advanced negotiations to sell Xellia Pharmaceuticals AS, reported Reuters citing two people familiar with the matter. The report added that the sale of Xellia could fetch €750 million. Linklaters is acting as legal adviser to 3i. A 3i spokesperson was not available for comment. Linklaters did not immediately return a request for comment.
Xellia Pharmaceuticals announced that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria. This four year development project at Xellia is a collaboration with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen). The project is being supported by a $3 million grant from the Research Council of Norway (NFR). The project also includes contributions from laboratories across Europe. Xellia is aiming to develop new antibiotics that target Gram-negative bacterial infections, caused by, for example Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species. Severe sepsis and septic shock due to such infections take up to 135,000 lives each year in Europe and 215,000 in USA. Resistance to existing antibiotics has become a major healthcare issue worldwide. In the EU alone, infections due to serious hospital-based MDR infections have been reported to cost between EUR 28,500 (in hospital units and ICUs) and EUR 70,100 (in MDR ICUs) per surviving patient. Recently, pan-drug resistant (PDR) and even so-called extensively drug resistant (XDR) Gram-negative bacteria have started to appear, taking the treatment situation to a critical point. The lack of novel antibiotics is significantly compromising the survival and recovery of patients suffering from these infections. At present, only two antibiotic subclasses are still available to treat XDR infections, polymyxins and tigecycline.
Similar Private Companies By Industry
| Company Name | Region |
| AME Bioscience A/S | Europe |
| Pronova BioPharma ASA | Europe |
| EPAX A.S. | Europe |
| PCI Biotech AS | Europe |
| Orthogentics A/S | Europe |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Citizens Budget Commission | United States |
Post a JobJobs
- Greenville, NC | Vidant Medical CenterPosted: May 15
- New Brunswick, NJ | Tridiagonal SolutionsPosted: Apr 24
- Atlantic City, NJ | Pat Licata & AssociatesPosted: May 19
- Souderton, PA | Hire IT PeoplePosted: May 18
Sponsored Financial Commentaries
Sponsored Links
To contact Xellia Pharmaceuticals AS, please visit www.xellia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
